Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FQWM7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $79,460
Award facts
- Contract value 100% obligated
- $79,460.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $79,460 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The delivery order, issued on January 28, 2026, with an ultimate completion date of January 29, 2026, contains no set-aside designation, indicating the award was made through open competition. DMS Pharmaceutical Group is fulfilling this requirement under its single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion federal acquisition strategy designed to provide comprehensive pharmaceutical supply to Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with the underlying IDC contract valued at approximately $500 million and extending through December 31, 2036. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, positioning it to address the diverse therapeutic requirements of military healthcare operations globally. This delivery order represents one of numerous purchase orders issued through the PPV-G GEN V program, demonstrating the contractor's consistent performance and capability to support recurring pharmaceutical supply needs across the Department of Defense medical system.
Quick answers
Who was awarded contract SPE2DR26FQWM7?
SPE2DR26FQWM7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FQWM7 worth?
The government has obligated $79,460 on SPE2DR26FQWM7.
Is contract SPE2DR26FQWM7 an order under another contract?
Yes. SPE2DR26FQWM7 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWM7 competed?
The extent of competition for SPE2DR26FQWM7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award